334 related articles for article (PubMed ID: 22530845)
1. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
Peterson G
Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
[TBL] [Abstract][Full Text] [Related]
2. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
3. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
4. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
5. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
van Genugten RE; van Raalte DH; Diamant M
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
[TBL] [Abstract][Full Text] [Related]
6. The effects of glucagon-like peptide-1 on the beta cell.
Vilsbøll T
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
[TBL] [Abstract][Full Text] [Related]
7. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
8. Distinguishing among incretin-based therapies. Introduction.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
[TBL] [Abstract][Full Text] [Related]
9. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.
Aroda VR; Ratner R
Diabetes Metab Res Rev; 2011 Sep; 27(6):528-42. PubMed ID: 21484979
[TBL] [Abstract][Full Text] [Related]
10. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
11. Incretins and their role in the management of diabetes.
Frias JP; Edelman SV
Curr Opin Endocrinol Diabetes Obes; 2007 Aug; 14(4):269-76. PubMed ID: 17940451
[TBL] [Abstract][Full Text] [Related]
12. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Bourdel-Marchasson I; Schweizer A; Dejager S
Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
[TBL] [Abstract][Full Text] [Related]
13. Incretin physiology and its role in type 2 diabetes mellitus.
Svec F
J Am Osteopath Assoc; 2010 Jul; 110(7 Suppl 7):eS20-4. PubMed ID: 20644202
[TBL] [Abstract][Full Text] [Related]
14. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
Martin CL
Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
Bode B
Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658
[TBL] [Abstract][Full Text] [Related]
16. Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S20-7. PubMed ID: 20824236
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
Unger J
J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296
[TBL] [Abstract][Full Text] [Related]
18. GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes.
Holst JJ; Seino Y
Diabetes Res Clin Pract; 2009 Jul; 85(1):1-3. PubMed ID: 19299027
[No Abstract] [Full Text] [Related]
19. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists.
Hansen KB; Knop FK; Holst JJ; Vilsbøll T
Int J Clin Pract; 2009 Aug; 63(8):1154-60. PubMed ID: 19624785
[TBL] [Abstract][Full Text] [Related]
20. Combination pharmacotherapy with incretins: what works best and when?
Over RK; Ratner RE
Curr Diab Rep; 2008 Oct; 8(5):361-7. PubMed ID: 18778584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
